(2S,3S,5R)-2-methyloxane-3,4,5-triol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (2S,3S,5R)-2-methyloxane-3,4,5-triol
• 化学式: C₆H₁₂O₄
• 分子量: 148.16
• InChiKey: KBVSUNBCTPQWJL-JMSAOHGTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  69.9
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] GLUCOSE CONJUGATES OF TRIPTOLIDE, ANALOGS AND USES THEREOF<br/>[FR] CONJUGUÉS GLUCOSE DE TRIPTOLIDE, ANALOGUES ET UTILISATIONS CORRESPONDANTS
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2017136739A1

  公开（公告）日：2017-08-10

  Provided are compounds generated by conjugation of triptolide with glucose to form glucose-triptolide conjugates, provides compounds with effective anti -proliferative activity and improved tolerability as compared to naturally occurring triptolide compounds.

  提供了由三尖杉酯与葡萄糖结合形成的葡萄糖-三尖杉酯共轭物，这些化合物具有有效的抗增殖活性，并且相比自然存在的三尖杉酯化合物具有更好的耐受性。
• TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF
  申请人：Gin David

  公开号：US20110300177A1

  公开（公告）日：2011-12-08

  The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.

  本发明涉及三萜糖苷皂苷衍生的佐剂、其合成、中间体及其用途。QS-7是一种强效的免疫佐剂，其毒性显著低于QS-21，QS-21是目前在抗癌和抗病毒疫苗中被广泛使用的相关皂苷佐剂。繁琐的分离和纯化方案阻碍了QS-7的临床开发。本发明提供了一种新的半合成方法，其中使用水解的原皂苷混合物来合成QS-7、QS-21和相关的类似物，极大地促进了QS-7和QS-21类似物的临床前和临床评估。
• TRITERPENE SAPONINS, METHODS OF SYNTHESIS AND USES THEREOF
  申请人：MEMORIAL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

  公开号：US20150086585A1

  公开（公告）日：2015-03-26

  The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.

  本发明涉及以三萜甙苷皂苷为基础的佐剂，其合成，中间体以及使用方法。 QS-7是一种强效的免疫佐剂，其毒性明显低于QS-21，QS-21是当前抗癌和抗病毒疫苗中受欢迎的佐剂。繁琐的分离和纯化协议阻碍了QS-7的临床开发。提供了一种新的半合成方法，其中使用水解的原皂苷混合物来合成QS-7，QS-21和相关类似物，极大地促进了QS-7和QS-21类似物的临床前和临床评估。
• REVERSIBLE NATURAL PRODUCT GLYCOSYLTRANSFERASE-CATALYZED REACTIONS, COMPOUNDS AND RELATED METHODS
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：US20150141294A1

  公开（公告）日：2015-05-21

  The present invention relates to methods of use of glycosyltransferases and related novel compounds. The invention exploits the reversibility of glycosyltransferases to generate new sugars, unnatural biomolecules and numerous one-pot reactions for generation of new biomolecules having varied backbones such as enediynes, vancomycins, bleomycins, anthracyclines, macrolides, pluramycins, aureolic acids, indolocarbazoles, aminglycosides, glycopeptides, polyenes, coumarins, benzoisochromanequinones, calicheamicins, erythromycin, avermectins, ivermectins, angucyclines, cardiac glycosides, steroids or flavinoids. In preferred embodiments, the invention specifically relates to biosynthesis of anticancer (the enediyne calicheamicin, CLM), anthelmintic agents (the macrolides avermectin, ivermectin and erythromycin) and antibiotic (the glycopeptide vancomycin, VCM) natural product-based drugs developed by reversible, bidirectional glycosyltransferase-catalyzed reactions.
• US8841092B2
  申请人：——

  公开号：US8841092B2

  公开（公告）日：2014-09-23